AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31174889 — intervention group
Group type: EXPERIMENTAL
Intervention: ipafricept (IPA) in combination with carboplatin (C) and paclitaxel (P)
Number of subjects: 37
Study 31174889 — intervention group
Group type: EXPERIMENTAL
Intervention: ipafricept (IPA)
Number of subjects: 37
Study 29141087 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise + GM-CSF (n=53)
Number of subjects: 210
Study 29141087 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF alone (n=53)
Number of subjects: 210
Study 29141087 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise alone (n=53)
Number of subjects: 210
Study 29141087 — intervention group
Group type: COMPARATOR
Intervention: Attention control + placebo (n=51)
Number of subjects: 210
Study 26774378 — intervention group
Group type: EXPERIMENTAL
Intervention: Educator-led gross motor skill and physical activity program
Number of subjects: 150
Study 26774378 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 150
Study 23752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized endurance-training distribution (PET)
Number of subjects: 30
Study 23752040 — intervention group
Group type: COMPARATOR
Intervention: Moderately high-intensity (between-thresholds) endurance-training program (BThET)
Number of subjects: 30
Study 23752040 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset analysis of PET (n = 6)
Number of subjects: 30
Study 22791118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS), treated once daily for 4 weeks.
Number of subjects: 0
Study 22791118 — intervention group
Group type: COMPARATOR
Intervention: Placebo, treated once daily for 4 weeks.
Number of subjects: 0
Study 19517902 — intervention group
Group type: EXPERIMENTAL
Intervention: Reports of RCTs
Number of subjects: 54
Study 17563998 — intervention group
Group type: EXPERIMENTAL
Intervention: Konsol
Number of subjects: 100
Study 17563998 — intervention group
Group type: EXPERIMENTAL
Intervention: Konsol MF
Number of subjects: 100
Study 17563998 — intervention group
Group type: COMPARATOR
Intervention: St. Thomas
Number of subjects: 100
Study 15361093 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injection followed by graded pneumatic dilatation (PD) with 30 mm balloons
Number of subjects: 12
Study 15361093 — intervention group
Group type: COMPARATOR
Intervention: Control group treated only with graded pneumatic dilatation (PD)
Number of subjects: 12
Study 11848530 — intervention group
Group type: EXPERIMENTAL
Intervention: Total androgen ablation before RP
Number of subjects: 192
Study 11848530 — intervention group
Group type: COMPARATOR
Intervention: No total androgen ablation before RP
Number of subjects: 192
Study 9595980 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C-methionine PET
Number of subjects: 196
Study 9595980 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 196
Study 9595980 — intervention group
Group type: COMPARATOR
Intervention: Threshold differentiation
Number of subjects: 196
Study 9595980 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent or residual tumors
Number of subjects: 196
Study 7947417 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol treatment (on medication)
Number of subjects: 13
Study 7947417 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-free baseline (off medication)
Number of subjects: 13
Study 7947417 — intervention group
Group type: COMPARATOR
Intervention: Stable schizophrenic outpatients (n = 12)
Number of subjects: 13
Study 2976414 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting GnRH agonist (100-500 micrograms daily)
Number of subjects: 119
Study 2976414 — intervention group
Group type: COMPARATOR
Intervention: Long-acting GnRH agonist (3.2 mg bolus)
Number of subjects: 119
Study 2976414 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with elevated LH/FSH ratio
Number of subjects: 119
Study 2976414 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined GnRH-agonist/gonadotrophin stimulation
Number of subjects: 119
Study 29450895 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic action tendency retraining
Number of subjects: 72
Study 29450895 — intervention group
Group type: COMPARATOR
Intervention: Control condition (sham training)
Number of subjects: 72
Study 27424879 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct extraction of third molars with acute pulpitis (Group A)
Number of subjects: 60
Study 27424879 — intervention group
Group type: COMPARATOR
Intervention: Endodontic therapy followed by extraction (Group B)
Number of subjects: 60
Study 27424879 — intervention group
Group type: COMPARATOR
Intervention: Direct extraction of third molars without acute pulpitis (Group C)
Number of subjects: 60
Study 24986722 — intervention group
Group type: EXPERIMENTAL
Intervention: TNT at 608 kPa (6 atm abs)
Number of subjects: 139
Study 24986722 — intervention group
Group type: COMPARATOR
Intervention: TNT at 101.3 kPa (normal conditions)
Number of subjects: 139
Study 22672237 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.15 mol L(‐1) HCl infusion
Number of subjects: 25
Study 22672237 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 25
Study 20379739 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicitis-score-group (n = 96)
Number of subjects: 177
Study 20379739 — intervention group
Group type: COMPARATOR
Intervention: No-score-group (n = 81)
Number of subjects: 177
Study 18573823 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin as add-on therapy to interferon-beta 1b
Number of subjects: 0
Study 18573823 — intervention group
Group type: COMPARATOR
Intervention: Interferon-beta 1b
Number of subjects: 0
Study 16085593 — intervention group
Group type: EXPERIMENTAL
Intervention: mu-opioid receptor binding in bulimic subjects
Number of subjects: 16
Study 16085593 — intervention group
Group type: COMPARATOR
Intervention: Control group (female controls)
Number of subjects: 16
Study 12451158 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social support
Number of subjects: 243
Study 12451158 — intervention group
Group type: EXPERIMENTAL
Intervention: Burden
Number of subjects: 243
Study 12451158 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 243
Study 12451158 — intervention group
Group type: EXPERIMENTAL
Intervention: Hours of informal care
Number of subjects: 243
Study 12451158 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral problems
Number of subjects: 243
Study 12451158 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequency of getting a break
Number of subjects: 243
Study 11561574 — intervention group
Group type: EXPERIMENTAL
Intervention: Isepamicin
Number of subjects: 41
Study 11561574 — intervention group
Group type: COMPARATOR
Intervention: Amikacin
Number of subjects: 41
Study 8983446 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum IL-4 concentration (0.06 ng/ml)
Number of subjects: 35
Study 8983446 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum GM-CSF concentration (4.4 pg/ml)
Number of subjects: 35
Study 8195848 — intervention group
Group type: EXPERIMENTAL
Intervention: Brodimoprim (single dose)
Number of subjects: 0
Study 8195848 — intervention group
Group type: COMPARATOR
Intervention: Co-trimoxazole (trimethoprim 160 mg + sulphamethoxazole 800 mg every 12 hours)
Number of subjects: 0
Study 8195848 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (600 mg three times a day)
Number of subjects: 0
Study 3763654 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% fusidic acid plus 0.1% betamethasone cream
Number of subjects: 99
Study 3763654 — intervention group
Group type: COMPARATOR
Intervention: 0.1% gentamicin plus 0.1% betamethasone cream
Number of subjects: 99
Study 29696360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and gemcitabine with folic acid and vitamin B12 supplementation
Number of subjects: 82
Study 29696360 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine without folic acid and vitamin B12 supplementation (control)
Number of subjects: 82
Study 27583311 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 336
Study 27583311 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 336
Study 25924781 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (PEEP: 5 cm H2O, flow: 15 L/min, FiO2: 33 %) three times per week during hemodialysis sessions
Number of subjects: 40
Study 25924781 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 22177779 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective endoscopic treatment of non-refluxing contralateral ureters (NRCU) in patients deemed at high risk (H2 or H3)
Number of subjects: 339
Study 22177779 — intervention group
Group type: COMPARATOR
Intervention: Observation of non-refluxing contralateral ureters (NRCU) without treatment
Number of subjects: 339
Study 21400196 — intervention group
Group type: EXPERIMENTAL
Intervention: 20,000 IU vitamin D(3) weekly and 500 mg calcium daily for 96 weeks
Number of subjects: 71
Study 21400196 — intervention group
Group type: COMPARATOR
Intervention: Placebo and 500 mg calcium daily for 96 weeks
Number of subjects: 71
Study 18339525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline for 6 months
Number of subjects: 40
Study 18339525 — intervention group
Group type: COMPARATOR
Intervention: Standard measures
Number of subjects: 40
Study 16469753 — intervention group
Group type: COMPARATOR
Intervention: CVD regimen (cisplatin 30 mg/m2 on days 1-3, vindesine 2.5 mg/m2 on day 1, dacarbazine 250 mg/m2 on days 1-3)
Number of subjects: 151
Study 16469753 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD regimen plus interferon-alpha2b (days 1-5) and interleukin-2 (days 1-5 and 8-15)
Number of subjects: 151
Study 12906896 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-MDE
Number of subjects: 4
Study 12906896 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-MDE
Number of subjects: 4
Study 12906896 — intervention group
Group type: EXPERIMENTAL
Intervention: HME and MDA metabolites
Number of subjects: 4
Study 11146955 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous in‐line blood gas management (CILBGM)
Number of subjects: 59
Study 11146955 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sampling (control group)
Number of subjects: 59
Study 7484483 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate conservative management
Number of subjects: 0
Study 7484483 — intervention group
Group type: COMPARATOR
Intervention: Delayed conservative management
Number of subjects: 0
Study 2250128 — intervention group
Group type: EXPERIMENTAL
Intervention: COMPAS (computer-based patient advice system)
Number of subjects: 5
Study 7016150 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprenolol (5-10 mg intravenously followed by 200 mg orally twice a day for one year)
Number of subjects: 282
Study 7016150 — intervention group
Group type: COMPARATOR
Intervention: Placebo (5-10 mg intravenously followed by placebo orally twice a day for one year)
Number of subjects: 282
Study 30676617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg)
Number of subjects: 281
Study 30676617 — intervention group
Group type: COMPARATOR
Intervention: Aflibercept (2.0 mg)
Number of subjects: 281
Study 30676617 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab and Aflibercept
Number of subjects: 281
Study 28274562 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biopsy
Number of subjects: 637
Study 28274562 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized patients (no intervention)
Number of subjects: 637
Study 26048069 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) therapy with lidocaine and bupivacaine
Number of subjects: 37
Study 26048069 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile 0.9% saline)
Number of subjects: 37
Study 23835559 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern knee implant
Number of subjects: 0
Study 23835559 — intervention group
Group type: COMPARATOR
Intervention: Traditional knee implant
Number of subjects: 0
Study 21451348 — intervention group
Group type: EXPERIMENTAL
Intervention: MOTR (motive-oriented therapeutic relationship)
Number of subjects: 25
Study 21451348 — intervention group
Group type: COMPARATOR
Intervention: Manual-based investigation process
Number of subjects: 25
Study 19454394 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-daily insulin lispro mix 75/25 plus metformin
Number of subjects: 0
Study 19454394 — intervention group
Group type: EXPERIMENTAL
Intervention: Three times daily insulin lispro mix 50/50 plus metformin
Number of subjects: 0
Study 19454394 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine plus metformin
Number of subjects: 0
Study 16725261 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid blockade (8mg naloxone i.v.)
Number of subjects: 119
Study 16725261 — intervention group
Group type: COMPARATOR
Intervention: Placebo blockade (saline)
Number of subjects: 119
Study 16725261 — intervention group
Group type: COMPARATOR
Intervention: Finger pressure pain task
Number of subjects: 119
Study 15531001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10-40 mg
Number of subjects: 2268
Study 15531001 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (milligram-equivalent doses)
Number of subjects: 2268
Study 15531001 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin (milligram-equivalent or higher doses)
Number of subjects: 2268
Study 15531001 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (milligram-equivalent or higher doses)
Number of subjects: 2268
Study 15531001 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg
Number of subjects: 2268
Study 11234973 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid restriction
Number of subjects: 0
Study 11234973 — intervention group
Group type: COMPARATOR
Intervention: Maintenance therapy
Number of subjects: 0
Study 9028341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) treatment
Number of subjects: 150
Study 7930199 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal coil as the anode
Number of subjects: 20
Study 7930199 — intervention group
Group type: COMPARATOR
Intervention: Distal coil as the cathode
Number of subjects: 20
Study 3284726 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine, 0.5 mg, administered intramuscularly every third hour on the third day after laparotomy, until passage of flatus or stools or a total of three injections
Number of subjects: 90
Study 3284726 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 90
Study 31241854 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal PRP alone
Number of subjects: 30
Study 31241854 — intervention group
Group type: COMPARATOR
Intervention: Combined treatment with subcision followed by PRP injection
Number of subjects: 30
Study 30802941 — intervention group
Group type: EXPERIMENTAL
Intervention: Emyna (eCBT intervention)
Number of subjects: 200
Study 30802941 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 200
Study 28087552 — intervention group
Group type: EXPERIMENTAL
Intervention: AliveCor
Number of subjects: 421
Study 28087552 — intervention group
Group type: EXPERIMENTAL
Intervention: WatchBP
Number of subjects: 421
Study 28087552 — intervention group
Group type: EXPERIMENTAL
Intervention: Polar H7 heart rate monitor
Number of subjects: 421
Study 28087552 — intervention group
Group type: EXPERIMENTAL
Intervention: Firstbeat Bodyguard 2
Number of subjects: 421
Study 28087552 — intervention group
Group type: COMPARATOR
Intervention: 12-lead ECG
Number of subjects: 421
Study 25497264 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in diabetic patients
Number of subjects: 3014
Study 25497264 — intervention group
Group type: COMPARATOR
Intervention: Non-insulin treatment in diabetic patients
Number of subjects: 3014
Study 25497264 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 3014
Study 25497264 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic patients
Number of subjects: 3014
Study 24432627 — intervention group
Group type: EXPERIMENTAL
Intervention: Yiqi Zhujing Granule (1 packet, bid) for 3 months
Number of subjects: 78
Study 24432627 — intervention group
Group type: COMPARATOR
Intervention: Zinc gluconate liquid (10 ml, bid) and vitamin E (100 mg, bid) for 3 months (Control)
Number of subjects: 78
Study 21354628 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed hospital personnel during the Gaza War
Number of subjects: 268
Study 21354628 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposed hospital personnel 6 months later
Number of subjects: 268
Study 21354628 — intervention group
Group type: COMPARATOR
Intervention: Unexposed hospital personnel
Number of subjects: 268
Study 18156535 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg oral dexamethasone
Number of subjects: 63
Study 18156535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 16925730 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF)
Number of subjects: 600
Study 16925730 — intervention group
Group type: COMPARATOR
Intervention: Stavudine (d4T)
Number of subjects: 600
Study 12881374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mammographic screening
Number of subjects: 0
Study 12881374 — intervention group
Group type: EXPERIMENTAL
Intervention: Case-control studies
Number of subjects: 0
Study 12881374 — intervention group
Group type: COMPARATOR
Intervention: Randomised trials
Number of subjects: 0
Study 10989897 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous fascial closure
Number of subjects: 331
Study 10989897 — intervention group
Group type: COMPARATOR
Intervention: Interrupted fascial closure
Number of subjects: 331
Study 8833622 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-carbohydrate diet
Number of subjects: 216
Study 8833622 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 216
Study 8833622 — intervention group
Group type: COMPARATOR
Intervention: Pilot studies participants
Number of subjects: 216
Study 1483439 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO
Number of subjects: 8
Study 1483439 — intervention group
Group type: EXPERIMENTAL
Intervention: 12% CHO
Number of subjects: 8
Study 1483439 — intervention group
Group type: COMPARATOR
Intervention: Placebo (water)
Number of subjects: 8
Study 2931831 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30-80 mg daily)
Number of subjects: 200
Study 2931831 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 31283822 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine supplementation (6-month duration)
Number of subjects: 9
Study 31283822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (6-month duration)
Number of subjects: 9
Study 29982704 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined carbohydrate-enriched diet
Number of subjects: 11
Study 29982704 — intervention group
Group type: COMPARATOR
Intervention: Simple carbohydrate-enriched diet
Number of subjects: 11
Study 29982704 — intervention group
Group type: COMPARATOR
Intervention: Unrefined carbohydrate-enriched diet
Number of subjects: 11
Study 27881108 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended smoking cessation treatment (5 online sessions, 5 face-to-face sessions)
Number of subjects: 344
Study 27881108 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face smoking cessation treatment (10 face-to-face sessions)
Number of subjects: 344
Study 24549163 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary infusion of autologous bone marrow mononuclear cells (BMCs)
Number of subjects: 100
Study 24549163 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 100
Study 22676495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellar resurfacing (Resurfaced group)
Number of subjects: 38
Study 22676495 — intervention group
Group type: COMPARATOR
Intervention: Patellar retention (Non-resurfaced group)
Number of subjects: 38
Study 20925951 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy
Number of subjects: 0
Study 20925951 — intervention group
Group type: COMPARATOR
Intervention: Fractionated stereotactic radiotherapy (FSRT) with a total dose of 36 Gy in single doses of 2 Gy
Number of subjects: 0
Study 16996154 — intervention group
Group type: EXPERIMENTAL
Intervention: Oligofructose (OF) supplementation
Number of subjects: 0
Study 16996154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16327491 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamp crushing technique
Number of subjects: 100
Study 16327491 — intervention group
Group type: COMPARATOR
Intervention: CUSA
Number of subjects: 100
Study 16327491 — intervention group
Group type: COMPARATOR
Intervention: Hydrojet
Number of subjects: 100
Study 16327491 — intervention group
Group type: COMPARATOR
Intervention: Dissecting sealer
Number of subjects: 100
Study 12072875 — intervention group
Group type: COMPARATOR
Intervention: Nonlitigious questionnaire
Number of subjects: 1000
Study 12072875 — intervention group
Group type: EXPERIMENTAL
Intervention: Litigious questionnaire
Number of subjects: 1000
Study 12072875 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental litigiousness influence
Number of subjects: 1000
Study 9469496 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium ketoglutarate
Number of subjects: 19
Study 9469496 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate
Number of subjects: 19
Study 7703872 — intervention group
Group type: EXPERIMENTAL
Intervention: Accu‐Easy
Number of subjects: 101
Study 7703872 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucometer Encore
Number of subjects: 101
Study 7703872 — intervention group
Group type: COMPARATOR
Intervention: Both monitors
Number of subjects: 101
Study 2710173 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium acetate (4.4 g, 25 mmol of calcium)
Number of subjects: 6
Study 2710173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1102394 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl
Number of subjects: 0
Study 1102394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30924600 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen matrix implant (Ologen®; OLO)
Number of subjects: 45
Study 30924600 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin C (MMC)
Number of subjects: 45